HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
NA | Cabozantinib | Cabometyx | 60 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2012 | In Use | |||
NA | Polyestradiol Phosphate | Estradurin, Estradurine | 40 mg | Hormonal Therapy | Estrogen Derivative | No | 1957 | Aug 8, 2003 | No Longer Used | |||
NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
NA | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 15 mg | Ancillary Therapy | Chemoprotective | Antidote | Yes | 1952 | Jan 1, 1997 | In Use | ||
NA | Hydrocortisone | Cortef | 5mg, 10mg, 20mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1952 | In Use | |||
NA | Uracil Mustard | Uramustine | unspecified | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1962 | 1999 | No Longer Used | ||
NA | Dasatinib | Sprycel | 50 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Darolutamide | Nubeqa | 300mg | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Yes | 2019 | In Use | |||
NA | Lenalidomide | Revlimid | 10 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 2005 | In Use | |||
NA | Dinutuximab | Unituxin | 3.5 mg/mL | Immunotherapy | Monoclonal Antibody | GD-2 | No | 2015 | In Use | |||
NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 0.3 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
NA | Encorafenib | Braftovi | 50mg, 75mg | Chemotherapy | BRAF Inhibitor | V600E | Yes | 2018 | In Use | |||
NA | Brigatinib | Alunbrig | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2017 | In Use | |||
NA | Dasatinib | Sprycel | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Lorlatinib | Lorbrena | 25mg, 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Yes | 2018 | In Use | |||
NA | Prednisolone Tebutate | Hydeltra-TBA, Norpred TBA, Predalone T.B.A., Predate TBA, Predcor TBA, Prednisol TBA, Prednisolone TBA, TBA Pred | 20 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1956 | 2003 | In Use | ||
NA | Alectinib | Alecensa | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2015 | In Use | |||
NA | Dasatinib | Sprycel | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
NA | Entrectinib | Rozlytrek | 100mg, 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Yes | 2019 | In Use | |||
NA | Dabrafenib | Tafinlar | 75 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BRAF | Yes | 2013 | Jan 1, 2004 | In Use | ||
NA | Umbralisib | Ukoniq | 260.2mg | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Yes | 2021 | In Use | |||
NA | Zanubrutinib | Brukinsa | 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2019 | In Use | |||
NA | Nintedanib | Ofev | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use | |||
NA | Cysteamine Bitartrate | Procysbi | 25mg, 75mg, 300mg | Chemotherapy | Cystine-Depleting Agent | Yes | 2013 | In Use | ||||
NA | Enasidenib mesylate | Idhifa | 50 mg | Chemotherapy | Enzyme Inhibitor | IDH2 | Yes | 2017 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.